Adaptive Biotechnologies poised for big growth in 2020

Adaptive Biotechnologies Corp., which is working to translate human immune system genes to identify and treat diseases, saw “incredible growth” in 2019, and CEO Chad Robins expects an even bigger year in 2020. Robins said during an earnings call Wednesday that he expect revenue in 2020 to range between $114 million and $119 million. Adaptive estimates its portfolio could be worth $48.7 billion, including $31.4 bill ion for cellular therapy in oncology. Last year, the company’s revenue was…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news